Literature DB >> 28402723

Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.

Annalisa Pezzolo1, Angela Rita Sementa2, Margherita Lerone3, Martina Morini4, Marzia Ognibene1, Raffaella Defferrari2, Katia Mazzocco2, Massimo Conte5, Anna Rita Gigliotti5, Alberto Garaventa5, Vito Pistoia6, Luigi Varesio4.   

Abstract

BACKGROUND: Neuroblastoma (NB) is a common and often lethal cancer of early childhood that accounts for 10% of pediatric cancer mortality. Incidence peaks in infancy and then rapidly declines, with less than 5% of cases diagnosed in children and adolescents ≥ 10 y. There is increasing evidence that NB has unique biology and an chronic disease course in older children and adolescents, but ultimately dismal survival.
METHODS: We describe a rare constitutional 3p26.3 terminal microdeletion which occurred in an adolescent with NB, with apparently normal phenotype without neurocognitive defects. We evaluated the association of expression of genes involved in the microdeletion with NB patient outcomes using R2 platform. We screened NB patient's tumor cells for CHL1 protein expression using immunofluorescence.
RESULTS: Constitutional and tumor DNA were tested by array-comparative genomic hybridization and single nucleotide-polymorphism-array analyses. Peripheral blood mononuclear cells from the patient showed a 2.54 Mb sub-microscopic constitutional terminal 3p deletion that extended to band p26.3. The microdeletion 3p disrupted the CNTN4 gene and the neighboring CNTN6 and CHL1 genes were hemizygously deleted, each of these genes encode neuronal cell adhesion molecules. Low expression of CNTN6 and CNTN4 genes did not stratify NB patients, whereas low CHL1 expression characterized 417 NB patients having worse overall survival. CHL1 protein expression on tumor cells from the patient was weaker than positive control.
CONCLUSION: This is the first report of a constitutional 3p26.3 deletion in a NB patient. Since larger deletions of 3p, indicative of the presence of one or more tumor suppressor genes in this region, occur frequently in neuroblastoma, our results pave the way to the identification of one putative NB suppressor genes mapping in 3p26.3.

Entities:  

Keywords:  3p terminal deletion syndrome; 3p26.3 microdeletion; Array-CGH; germline structural chromosomal abnormalities; neuroblastoma

Mesh:

Year:  2017        PMID: 28402723      PMCID: PMC5499752          DOI: 10.1080/15384047.2017.1312231

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  27 in total

1.  Congenital neuroblastoma in a patient with partial trisomy of 2p.

Authors:  Yuri Dowa; Toshiyuki Yamamoto; Yasuko Abe; Masaki Kobayashi; Rikuo Hoshino; Kazumi Tanaka; Noriko Aida; Hiroshi Take; Keisuke Kato; Yukichi Tanaka; Jyunpei Ariyama; Naoki Harada; Naomichi Matsumoto; Kenji Kurosawa
Journal:  J Pediatr Hematol Oncol       Date:  2006-06       Impact factor: 1.289

Review 2.  Heterozygous deletion of CHL1 gene: detailed array-CGH and clinical characterization of a new case and review of the literature.

Authors:  Elisa Tassano; Roberta Biancheri; Laura Denegri; Simona Porta; Francesca Novara; Orsetta Zuffardi; Giorgio Gimelli; Cristina Cuoco
Journal:  Eur J Med Genet       Date:  2014 Nov-Dec       Impact factor: 2.708

3.  Cloning and characterization of the human neural cell adhesion molecule, CNTN4 (alias BIG-2).

Authors:  L M Hansford; S A Smith; M Haber; M D Norris; B Cheung; G M Marshall
Journal:  Cytogenet Genome Res       Date:  2003       Impact factor: 1.636

4.  Constitutional 1p36 deletion in a child with neuroblastoma.

Authors:  J A Biegel; P S White; H N Marshall; M Fujimori; E H Zackai; C D Scher; G M Brodeur; B S Emanuel
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

5.  CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior.

Authors:  Suzanna G M Frints; Peter Marynen; Dieter Hartmann; Jean-Pierre Fryns; Jean Steyaert; Melitta Schachner; Bettina Rolf; Katleen Craessaerts; An Snellinx; Karen Hollanders; Rudi D'Hooge; Peter P De Deyn; Guy Froyen
Journal:  Hum Mol Genet       Date:  2003-07-01       Impact factor: 6.150

6.  Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.

Authors:  Yaël P Mossé; Rebecca J Deyell; Frank Berthold; Akira Nagakawara; Peter F Ambros; Tom Monclair; Susan L Cohn; Andrew D Pearson; Wendy B London; Katherine K Matthay
Journal:  Pediatr Blood Cancer       Date:  2013-09-13       Impact factor: 3.167

7.  Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.

Authors:  Annalisa Passariello; Daniele De Brasi; Raffaella Defferrari; Rita Genesio; Maria Tufano; Katia Mazzocco; Maria Capasso; Roberta Migliorati; Tommy Martinsson; Paolo Siani; Lucio Nitsch; Gian Paolo Tonini
Journal:  Eur J Med Genet       Date:  2013-09-13       Impact factor: 2.708

8.  Neuroblastoma in monozygotic twins--a case of probable twin-to-twin metastasis.

Authors:  J Anderson; H Kempski; L Hill; D Rampling; T Gordon; A Michalski
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

9.  A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes.

Authors:  Karl Vandepoele; Vanessa Andries; Nadine Van Roy; Katrien Staes; Jo Vandesompele; Geneviève Laureys; Els De Smet; Geert Berx; Frank Speleman; Frans van Roy
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

10.  On the significance of germline cytogenetic rearrangements at MYCN locus in neuroblastoma.

Authors:  Beata S Lipska; Magdalena Koczkowska; Jolanta Wierzba; Anna Ploszynska; Mariola Iliszko; Ewa Izycka-Swieszewska; Elzbieta Adamkiewicz-Drozynska; Janusz Limon
Journal:  Mol Cytogenet       Date:  2013-10-16       Impact factor: 2.009

View more
  6 in total

Review 1.  Genetic susceptibility to neuroblastoma: current knowledge and future directions.

Authors:  Laura E Ritenour; Michael P Randall; Kristopher R Bosse; Sharon J Diskin
Journal:  Cell Tissue Res       Date:  2018-03-27       Impact factor: 5.249

2.  Increased expression of RBMS3 predicts a favorable prognosis in human gallbladder carcinoma.

Authors:  Youliang Wu; Delong Meng; Yexiang You; Ruochuan Sun; Qiang Yan; Junjun Bao; Yanjun Sun; Dapeng Yun; Yongxiang Li; Dengqun Sun
Journal:  Oncol Rep       Date:  2020-04-23       Impact factor: 3.906

3.  Recurrent chromosomal and epigenetic alterations in oral squamous cell carcinoma and its putative premalignant condition oral lichen planus.

Authors:  Christopher G Németh; Christoph Röcken; Reiner Siebert; Jörg Wiltfang; Ole Ammerpohl; Volker Gassling
Journal:  PLoS One       Date:  2019-04-09       Impact factor: 3.240

4.  CHL1 and NrCAM are Primarily Expressed in Low Grade Pediatric Neuroblastoma.

Authors:  Robin Wachowiak; Steffi Mayer; Anne Suttkus; Illya Martynov; Martin Lacher; Nathaniel Melling; Jakob R Izbicki; Michael Tachezy
Journal:  Open Med (Wars)       Date:  2019-12-31

5.  Genomic Analysis Made It Possible to Identify Gene-Driver Alterations Covering the Time Window between Diagnosis of Neuroblastoma 4S and the Progression to Stage 4.

Authors:  Marzia Ognibene; Patrizia De Marco; Stefano Parodi; Mariaclaudia Meli; Andrea Di Cataldo; Federico Zara; Annalisa Pezzolo
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

6.  CHL1 gene acts as a tumor suppressor in human neuroblastoma.

Authors:  Marzia Ognibene; Gabriella Pagnan; Danilo Marimpietri; Davide Cangelosi; Michele Cilli; Maria Chiara Benedetti; Renata Boldrini; Alberto Garaventa; Francesco Frassoni; Alessandra Eva; Luigi Varesio; Vito Pistoia; Annalisa Pezzolo
Journal:  Oncotarget       Date:  2018-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.